Quick answer
Programs differ substantially on whether somebody can remain on a prescribed opioid while attending. Some will work with the prescriber; others expect a reduction first or as a condition. That is worth establishing before admission rather than discovering in week two.
If this is an emergency
Call 911 if someone is unresponsive, having a seizure, breathing slowly or irregularly, or confused with a high fever. For a mental health or suicidal crisis, call or text 988 to reach the Suicide & Crisis Lifeline, available 24 hours a day. This website is not monitored in real time.
Key takeaways
- Ask the compatibility question — Not in week two.
- Never agree a fast reduction — That belongs to a prescriber.
- Document the prescription — Do not rely on testing.
- That is worth establishing before admission rather than discovering in week two.
What it isThe compatibility question
What varies between programs, plus a testing detail worth knowing.
Will they let you keep taking it — the rest of this section is what that means for oxycodone specifically.
Ask before you agree to anything
Put it plainly: can I attend while continuing my current prescription, and will you coordinate with my prescriber. A program that says yes will have a process for it. A program that expects reduction as a condition of attending is asking for something that has to be arranged with a prescriber and on a schedule, not agreed in an admissions call. Neither answer is wrong in itself; what causes harm is discovering the expectation after starting, when somebody is asked to reduce faster than is reasonable in order to stay in a program they have already committed to.
And a testing detail that surprises people
Oxycodone is a semi-synthetic and the general opiate immunoassay detects it unreliably, so a specific test has to be ordered. That has a practical consequence: a legitimate prescription may not appear where everybody expects it to, which is one more reason to have it documented on admission rather than assuming the panel will show it. Ask whether the program's testing includes a specific oxycodone assay, because a general screen is not doing what most people assume. The National Institute on Drug Abuse sets this out in more detail, and the full program is on the oxycodone treatment program.
The detailObligations and testing
Each item, and what it means in practice.
| Factor | What applies | Notes |
|---|---|---|
| Continuing the prescription | Programs differ | Ask before admission |
| Coordination with your prescriber | Ask directly | A yes has a process |
| Reduction as a condition | Needs a prescriber | Not an admissions call |
| Discovering it in week two | Where harm happens | Pressure to go faster |
| General opiate screen | Detects it unreliably | Semi-synthetic |
| A specific assay | Ask if included | Document regardless |
Not sure whether this applies to you? One conversation will tell you.
Talk to our admissions teamWhat to doWhat to establish first
Three things. Start with ask the compatibility question.
Before admission
Not in week two.
To keep a place
That belongs to a prescriber.
The panel may miss it
Do not rely on testing.
The full program is on treatment for oxycodone, withdrawal on withdrawal management for oxycodone, and what admission involves on the admissions page.
oxycodone treatment program — the full guide library
11 guidesWhat an assessment covers, and what families can actually do.
More on oxycodone
The bottom line
Ask before admission whether you can attend while continuing your prescription and whether they will coordinate with your prescriber. Discovering that expectation later is where the harm happens.
If you are considering treatment, ask about insurance coverage for care and paying for treatment before committing. Review the steps to admission before arranging your visit.
Evidence to use when planning care
Naloxone reverses opioid overdose and is an emergency response tool. It does not replace emergency help or the continuing assessment and treatment needed after an overdose. See CDC’s naloxone guidance.
Medication can be part of opioid use disorder treatment. Decisions about starting it, the timing of treatment and follow-up belong with a qualified clinician rather than a dose or schedule copied from a general web page. See NIDA’s explanation of buprenorphine treatment.
To compare qualified services, use treatment directories and then confirm the provider’s current services directly. A directory entry does not establish that a particular treatment, appointment or insurance arrangement is available to you. See SAMHSA’s treatment directories.
Frequently asked questions
For oxycodone addiction treatment program, can I attend a program while still prescribed an opioid?
It varies substantially between programs. Some will coordinate with your prescriber and others expect a reduction first or as a condition of attending.
For oxycodone addiction treatment program, what if reduction is a condition?
It has to be arranged with a prescriber and on a schedule rather than agreed in an admissions call. Do not commit to a pace to keep a place.
For oxycodone addiction treatment program, why ask before admission?
Because discovering the expectation after starting creates pressure to reduce faster than is reasonable in order to stay in a program already committed to.
For oxycodone addiction treatment program, will my prescription show on a drug test?
Not reliably on a general opiate screen, since oxycodone is a semi-synthetic. A specific assay has to be ordered.
Should I document it anyway?
Yes, on admission. Relying on a panel to reveal a legitimate prescription is unreliable in both directions.
What else is expected of me?
Attendance, participation, medication taken as prescribed, and reporting a lapse rather than concealing it.
When you are ready, we are here. Free, confidential, and no commitment.
Talk to our admissions teamHow this page was built and reviewed
This page argues that the question that decides whether a program fits is not about testing. it is whether continuing a prescribed opioid is compatible with being there. Every clinical statement behind that rests on the sources listed below. No dosing, price or outcome claim appears here.
References
- National Institute on Drug Abuse. Prescription opioids drug facts. https://nida.nih.gov/
- MedlinePlus, U.S. National Library of Medicine. Oxycodone and acetaminophen combination products. https://medlineplus.gov/
- American Society of Addiction Medicine. National practice guideline for the treatment of opioid use disorder. https://www.asam.org/
- Centers for Disease Control and Prevention. Prescription opioid overdose data and guidance. https://www.cdc.gov/
- California Department of Health Care Services. Licensed and certified SUD facility verification. https://www.dhcs.ca.gov/individuals/Pages/SUD-Licensed-Certified.aspx